Approval · Notice of Compliance 12529 · 2011
TWYNSTA: Notice of Compliance 12529
Issued August 3, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12529
- Date
- August 3, 2011
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- Angiotensin II AT1 Receptor Blocker / Clacium Channel Blocker
Products in this notice
Medicinal ingredients
- AMLODIPINE BESYLATE 5 MG per TAB
- TELMISARTAN 40 MG per TAB
- AMLODIPINE BESYLATE 10 MG per TAB
- TELMISARTAN 80 MG per TAB